# Implementation Phases

**Version:** 1.0.0
**Created:** December 29, 2025
**Status:** Planning Phase

---

## Overview

This document defines the phased implementation approach for the 100 features. Each phase builds upon previous phases, with clear entry and exit criteria.

---

## Phase 0: Foundation Hardening (Pre-requisite)
**Duration:** Baseline
**Theme:** Ensure existing infrastructure is production-ready

### Features
| ID | Feature | Priority | Rationale |
|----|---------|----------|-----------|
| - | Test coverage to 90% | Critical | Foundation for safe changes |
| - | Documentation audit | Critical | Enable team onboarding |
| - | CI/CD pipeline hardening | Critical | Automated quality gates |

### Entry Criteria
- All existing tests passing (2965+)
- No critical security vulnerabilities

### Exit Criteria
- Test coverage ≥90%
- All public APIs documented
- CI pipeline runs <10 minutes

---

## Phase 1: Clinical Foundation (Q1 2025)
**Duration:** 12 weeks
**Theme:** Enable clinical deployment readiness

### Features
| ID | Feature | Priority | Complexity | Dependencies |
|----|---------|----------|------------|--------------|
| 36 | Conformal Prediction | Critical | Medium | None |
| 37 | Temperature Scaling | Critical | Low | #36 |
| 51 | Self-Supervised Pre-training | Critical | High | None |
| 82 | Clinical Decision API | Critical | High | #36 |
| 16 | 5-adic Amino Acid Encoder | High | Medium | None |
| 91 | Mixed Precision Training | High | Low | None |

### Milestone Deliverables
1. **Week 4:** Conformal prediction integrated with calibrated confidence intervals
2. **Week 8:** Self-supervised pre-training pipeline operational
3. **Week 12:** Clinical Decision API deployed to staging

### Technical Dependencies
```
#36 Conformal Prediction
  └── #37 Temperature Scaling
       └── #82 Clinical Decision API

#51 Self-Supervised Pre-training (independent)
#16 5-adic Encoder (independent)
#91 Mixed Precision (independent)
```

### Entry Criteria
- Phase 0 complete
- Development environment standardized

### Exit Criteria
- Clinical API returns calibrated predictions
- Pre-training reduces downstream training by 30%
- All Phase 1 features have 100% test coverage

---

## Phase 2: Disease Expansion (Q2 2025)
**Duration:** 12 weeks
**Theme:** Expand pathogen coverage with high-impact diseases

### Features
| ID | Feature | Priority | Complexity | Dependencies |
|----|---------|----------|------------|--------------|
| 1 | Dengue Analyzer | Critical | High | #51 |
| 2 | Zika Analyzer | Critical | High | #51, #1 |
| 3 | Norovirus Analyzer | High | Medium | #51 |
| 4 | Enterovirus Analyzer | High | Medium | #51 |
| 56 | Hierarchical VAE | High | High | #51 |
| 57 | VQ-VAE for Codons | Medium | High | #16 |

### Milestone Deliverables
1. **Week 4:** Dengue analyzer with Spearman ≥0.75
2. **Week 8:** Zika, Norovirus analyzers operational
3. **Week 12:** Hierarchical VAE improves multi-disease performance

### Technical Dependencies
```
#51 Self-Supervised Pre-training
  ├── #1 Dengue Analyzer
  │    └── #2 Zika Analyzer (shared flavivirus patterns)
  ├── #3 Norovirus Analyzer
  ├── #4 Enterovirus Analyzer
  └── #56 Hierarchical VAE

#16 5-adic Encoder
  └── #57 VQ-VAE for Codons
```

### Entry Criteria
- Phase 1 complete
- Pre-training pipeline operational
- Clinical API stable

### Exit Criteria
- 4 new disease analyzers with Spearman ≥0.75
- Hierarchical VAE shows ≥5% improvement
- VQ-VAE codebook learned with good utilization

---

## Phase 3: Advanced Features (Q3 2025)
**Duration:** 12 weeks
**Theme:** Sophisticated modeling capabilities

### Features
| ID | Feature | Priority | Complexity | Dependencies |
|----|---------|----------|------------|--------------|
| 71 | Tensor Epistasis Network | Critical | Very High | #56 |
| 46 | Domain Adversarial Transfer | High | High | #51, #56 |
| 26 | Multi-Sheet Hyperbolic | High | Very High | None |
| 38 | Bayesian Neural Networks | High | High | #36 |
| 58 | Attention-Based VAE | Medium | High | #56 |
| 17 | 7-adic Secondary Structure | Medium | Medium | #16 |

### Milestone Deliverables
1. **Week 4:** Tensor epistasis detects known mutation pairs
2. **Week 8:** Domain adversarial improves cross-disease transfer
3. **Week 12:** Multi-sheet hyperbolic operational for hierarchical diseases

### Technical Dependencies
```
#56 Hierarchical VAE
  ├── #71 Tensor Epistasis
  ├── #46 Domain Adversarial Transfer
  └── #58 Attention-Based VAE

#36 Conformal Prediction
  └── #38 Bayesian Neural Networks

#26 Multi-Sheet Hyperbolic (independent, builds on existing hyperbolic)

#16 5-adic Encoder
  └── #17 7-adic Secondary Structure
```

### Entry Criteria
- Phase 2 complete
- 15+ disease analyzers operational
- Hierarchical VAE validated

### Exit Criteria
- Epistasis network detects 80% of known interactions
- Cross-disease transfer shows positive transfer
- Multi-sheet hyperbolic handles disease hierarchies

---

## Phase 4: Clinical Deployment (Q4 2025)
**Duration:** 12 weeks
**Theme:** Healthcare system integration

### Features
| ID | Feature | Priority | Complexity | Dependencies |
|----|---------|----------|------------|--------------|
| 81 | FHIR R4 Integration | Critical | Very High | #82 |
| 88 | Surveillance Dashboard | Critical | High | #82 |
| 83 | Automated Reports | High | Medium | #82 |
| 84 | Clinical Alerts | High | Medium | #82, #36 |
| 100 | Federated Learning | High | Very High | #51 |
| 85 | Drug Interaction Checker | Medium | Medium | #71 |

### Milestone Deliverables
1. **Week 4:** FHIR DiagnosticReport resources generated
2. **Week 8:** Surveillance dashboard with real-time updates
3. **Week 12:** Federated learning across 2+ simulated sites

### Technical Dependencies
```
#82 Clinical Decision API
  ├── #81 FHIR R4 Integration
  ├── #88 Surveillance Dashboard
  ├── #83 Automated Reports
  └── #84 Clinical Alerts
       └── #36 Conformal Prediction (confidence thresholds)

#51 Self-Supervised Pre-training
  └── #100 Federated Learning

#71 Tensor Epistasis
  └── #85 Drug Interaction Checker
```

### Entry Criteria
- Phase 3 complete
- Clinical API production-stable
- Security audit passed

### Exit Criteria
- FHIR compliance validated
- Dashboard handles 1000+ concurrent users
- Federated learning preserves privacy (DP guarantees)

---

## Phase 5: Scale & Optimize (Q1 2026)
**Duration:** 12 weeks
**Theme:** Production hardening and remaining disease analyzers

### Features
| ID | Feature | Priority | Complexity | Dependencies |
|----|---------|----------|------------|--------------|
| 5-15 | Remaining Disease Analyzers | High | Medium each | #51, #46 |
| 99 | Neural Architecture Search | High | Very High | #91 |
| 98 | Knowledge Distillation | High | High | #56 |
| 92 | Gradient Checkpointing | Medium | Low | None |
| 93 | Distributed Training | Medium | High | #91 |
| 94 | Dynamic Batching | Medium | Medium | #91 |

### Remaining Disease Analyzers (5-15)
| ID | Feature | Priority |
|----|---------|----------|
| 5 | West Nile Analyzer | High |
| 6 | Chikungunya Analyzer | High |
| 7 | HPV Analyzer | High |
| 8 | EBV Analyzer | Medium |
| 9 | CMV Analyzer | Medium |
| 10 | Adenovirus Analyzer | Medium |
| 11 | C. difficile Analyzer | High |
| 12 | E. coli Analyzer | High |
| 13 | Klebsiella Analyzer | High |
| 14 | Acinetobacter Analyzer | Medium |
| 15 | Pseudomonas Analyzer | Medium |

### Milestone Deliverables
1. **Week 4:** 5 additional disease analyzers (total 20)
2. **Week 8:** NAS discovers improved architecture
3. **Week 12:** All 26 disease analyzers operational

### Entry Criteria
- Phase 4 complete
- Clinical deployment stable
- Performance baselines established

### Exit Criteria
- 26 disease analyzers with Spearman ≥0.75
- NAS architecture matches or exceeds manual design
- 10M sequences/second inference throughput

---

## Phase 6: Research Frontier (Q2 2026)
**Duration:** 12 weeks
**Theme:** Cutting-edge research capabilities

### Features
| ID | Feature | Priority | Complexity | Dependencies |
|----|---------|----------|------------|--------------|
| 17-25 | Remaining Encoding Methods | Medium | Varies | #16, #17 |
| 27-35 | Advanced Hyperbolic | Medium | High-Very High | #26 |
| 72-80 | Full Epistasis Suite | Medium | High | #71 |
| 47-50 | Advanced Transfer | Medium | High | #46 |
| 86-90 | Research Tools | Medium | Medium | Various |

### Feature Groups

#### Remaining Encoding Methods (17-25)
| ID | Feature | Complexity |
|----|---------|------------|
| 18 | Multi-Prime Fusion | High |
| 19 | Adaptive Prime Selection | Very High |
| 20 | P-adic Wavelet | High |
| 21 | Codon Context Window | Medium |
| 22 | Position-Aware Encoding | Medium |
| 23 | Mutation-Type Embedding | Low |
| 24 | Reading Frame Encoding | Medium |
| 25 | Synonymous Codon Encoding | Medium |

#### Advanced Hyperbolic (27-35)
| ID | Feature | Complexity |
|----|---------|------------|
| 27 | Hyperbolic Normalizing Flows | Very High |
| 28 | Product Manifold Spaces | High |
| 29 | Adaptive Curvature | High |
| 30 | Hyperbolic Attention | High |
| 31 | Geodesic Interpolation | Medium |
| 32 | Hyperbolic Clustering | Medium |
| 33 | Busemann Functions | High |
| 34 | Hyperbolic Diffusion | Very High |
| 35 | Multi-Scale Hyperbolic | High |

#### Full Epistasis Suite (72-80)
| ID | Feature | Complexity |
|----|---------|------------|
| 72 | Sparse Epistasis | High |
| 73 | Temporal Epistasis | High |
| 74 | Cross-Gene Epistasis | Very High |
| 75 | Compensatory Mutations | Medium |
| 76 | Fitness Landscape | High |
| 77 | Evolutionary Trajectory | Very High |
| 78 | Mutation Order Effects | High |
| 79 | Codon-Level Epistasis | High |
| 80 | Structural Epistasis | Very High |

### Milestone Deliverables
1. **Week 4:** Multi-prime fusion encoder operational
2. **Week 8:** Advanced hyperbolic features validated
3. **Week 12:** Complete epistasis suite with visualization

### Entry Criteria
- Phase 5 complete
- All 26 disease analyzers operational
- Performance targets met

### Exit Criteria
- 4+ novel encoding methods validated
- 5+ hyperbolic innovations published
- Epistasis suite detects novel mutation interactions

---

## Cross-Phase Dependencies

```
Phase 0 ─────► Phase 1 ─────► Phase 2 ─────► Phase 3 ─────► Phase 4 ─────► Phase 5 ─────► Phase 6
Foundation    Clinical      Disease       Advanced       Clinical       Scale          Research
              Foundation    Expansion     Features       Deployment     Optimize       Frontier

Key Dependencies Across Phases:
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
#36 (P1) ──► #38 (P3) ──► #84 (P4)     Uncertainty chain
#51 (P1) ──► #46 (P3) ──► #100 (P4)    Transfer learning chain
#16 (P1) ──► #57 (P2) ──► #18-25 (P6)  Encoding evolution
#56 (P2) ──► #71 (P3) ──► #72-80 (P6)  Architecture/epistasis chain
#82 (P1) ──► #81 (P4) ──► #88 (P4)     Clinical integration chain
```

---

## Resource Allocation by Phase

| Phase | Engineering | Research | Clinical | Infrastructure |
|-------|-------------|----------|----------|----------------|
| 0 | 80% | 10% | 0% | 10% |
| 1 | 60% | 20% | 10% | 10% |
| 2 | 50% | 40% | 5% | 5% |
| 3 | 40% | 50% | 5% | 5% |
| 4 | 30% | 10% | 50% | 10% |
| 5 | 50% | 20% | 10% | 20% |
| 6 | 20% | 70% | 5% | 5% |

---

## Risk Mitigation by Phase

### Phase 1 Risks
- **Calibration accuracy**: Fallback to isotonic regression
- **API performance**: Implement caching layer

### Phase 2 Risks
- **Data availability**: Partner with public health agencies
- **Cross-pathogen transfer**: Use domain adversarial training

### Phase 3 Risks
- **Hyperbolic instability**: Use Lorentz model as stable fallback
- **Epistasis complexity**: Sparse factorization to reduce memory

### Phase 4 Risks
- **Regulatory delays**: Early FDA engagement
- **Security vulnerabilities**: Third-party audit before deployment

### Phase 5 Risks
- **NAS compute cost**: Use weight sharing to reduce search time
- **Model size**: Knowledge distillation for edge deployment

### Phase 6 Risks
- **Research uncertainty**: Treat as exploratory, not committed
- **Publication timeline**: Decouple from product releases

---

## Phase Completion Checklist

### Phase N Completion Requirements
- [ ] All phase features have 100% test coverage
- [ ] All phase features pass acceptance criteria
- [ ] Documentation updated
- [ ] Performance benchmarks met
- [ ] Security review passed (for clinical phases)
- [ ] Stakeholder sign-off obtained
- [ ] Retrospective completed
- [ ] Next phase planning finalized

---

## Change Log

| Date | Version | Changes |
|------|---------|---------|
| 2025-12-29 | 1.0.0 | Initial phases document |
